Pharvaris (PHVS) Other Working Capital Changes (2021 - 2026)
Pharvaris' (PHVS) quarterly Other Working Capital Changes came in at -$72017.2 in Q1 2026, up 34.51% YoY from -$53542.3 in Q1 2025, and up 6.71% on a QoQ basis from -$77194.7 in Q4 2025.
Pharvaris (PHVS) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Pharvaris (PHVS) has 5 years of Other Working Capital Changes data on file, last reported at -$72017.2 in Q1 2026.
- Quarterly Other Working Capital Changes rose 34.51% year-over-year to -$72017.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$204652.8 (up 8.77% YoY) and the FY2025 annual result came in at -$247443.3, down 43.19% from the prior year.
- Other Working Capital Changes climbed to -$72017.2 in Q1 2026, from -$77194.7 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $5285.8 billion in Q3 2023 to a low of -$5287.4 billion in Q2 2023.
- A 5-year average of -$95.6 million and a median of $234668.8 in 2025 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 270653106.85% in 2023, down 432447935.2% in 2023.
- Tracing PHVS's Other Working Capital Changes over 5 years: stood at -$47142.6 in 2022, then decreased by 24.74% to -$58805.5 in 2023, then surged by 51.7% to -$28403.3 in 2024, then slumped by 171.78% to -$77194.7 in 2025, then increased by 6.71% to -$72017.2 in 2026.
- The last three Other Working Capital Changes figures came in at -$72017.2 (Q1 2026), -$77194.7 (Q4 2025), and -$29100.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.15 Mn |
| Jun 30, 2026 | 3.15 Mn |
| Jun 30, 2026 | 3.15 Mn |
| Mar 31, 2026 | -1.44 Mn |
| Mar 31, 2026 | -1.44 Mn |
| Mar 31, 2026 | -1.44 Mn |
| Dec 31, 2025 | 234,668.84 |
| Dec 31, 2025 | 234,668.84 |
| Dec 31, 2025 | 234,668.84 |
| Sep 30, 2025 | 2.25 Mn |
| Sep 30, 2025 | 2.25 Mn |
| Sep 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | -1.36 Mn |
| Mar 31, 2025 | -1.36 Mn |
| Mar 31, 2025 | -1.36 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Dec 31, 2024 | -1.50 Mn |